Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome

被引：11

作者：

Kawanishi, C

Shimoda, Y

Fujimaki, J

Onishi, H

Suzuki, K

Hanihara, T

Sugiyama, N

Kosaka, K

机构：

[1] Yokohama City Univ, Sch Med, Dept Psychiat, Kanazawa Ku, Yokohama, Kanagawa 236, Japan

[2] Fujisawa Hosp, Fujisawa, Kanagawa 251, Japan

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 1998年 / 160卷 / 01期

关键词：

cytochrome P450IID6; CYP2D6J; neuroleptic; neuroleptic malignant syndrome; poor metabolizer; side effect;

D O I：

10.1016/S0022-510X(98)00238-X

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Cytochrome P450IID6 (CYP2DG) plays an important role in the hepatic metabolism of various psychotropic drugs. We detected a mutation of the CYP2D6 gene in two patients who previously had episodes of neuroleptic malignant syndrome (NMS). They were homozygous for a mutated CYP2D6J allele conferring a poor-metabolizer phenotype. Possession of this trait may contribute to susceptibility to NMS. (C) 1998 Elsevier Science B.V. All rights reserved.

引用

收藏

页码：102 / 104

页数：3

相关论文

共 12 条

[1]

THE CYTOCHROME-P450 CYP2D6 ALLELIC VARIANT CYP2D6J AND RELATED POLYMORPHISMS IN A EUROPEAN POPULATION [J].

ARMSTRONG, M ;

FAIRBROTHER, K ;

IDLE, JR ;

DALY, AK .

PHARMACOGENETICS, 1994, 4 (02) :73-81

[2]

DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].

BROLY, F ;

GAEDIGK, A ;

HEIM, M ;

EICHELBAUM, M ;

MORIKE, K ;

MEYER, UA .

DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558

[3]

GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN [J].

DAHL, ML ;

BERTILSSON, L .

PHARMACOGENETICS, 1993, 3 (02) :61-70

[4]

NEUROLEPTIC MALIGNANT SYNDROME - OBSERVATIONS ON ALTERED CONSCIOUSNESS [J].

DEUSCHL, G ;

OEPEN, G ;

HERMLE, L ;

KINDT, H .

PHARMACOPSYCHIATRY, 1987, 20 (04) :168-170

[5]

PHARMACOGENETIC PHENOTYPING AND GENOTYPING - PRESENT STATUS AND FUTURE POTENTIAL [J].

GONZALEZ, FJ ;

IDLE, JR .

CLINICAL PHARMACOKINETICS, 1994, 26 (01) :59-70

[6]

CYP2D6 GENOTYPE AND POSSIBLE SUSCEPTIBILITY TO THE NEUROLEPTIC MALIGNANT SYNDROME [J].

IWAHASHI, K .

BIOLOGICAL PSYCHIATRY, 1994, 36 (11) :781-782

[7]

Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B [J].

Kawanishi, C ;

Hanihara, T ;

Maruyama, Y ;

Matsumura, T ;

Onishi, H ;

Inoue, K ;

Sugiyama, N ;

Suzuki, K ;

Yamada, Y ;

Kosaka, K .

PSYCHIATRIC GENETICS, 1997, 7 (03) :127-129

[8]

IS THE PREDISPOSITION TO NEUROLEPTIC MALIGNANT SYNDROME GENETICALLY TRANSMITTED [J].

OTANI, K ;

HORIUCHI, M ;

KONDO, T ;

KANEKO, S ;

FUKUSHIMA, Y .

BRITISH JOURNAL OF PSYCHIATRY, 1991, 158 :850-853

[9]

POPE HG, 1986, AM J PSYCHIAT, V143, P1227

[10]

STRUCTURAL-CHANGE IN DOPAMINE D-2 RECEPTOR GENE IN A PATIENT WITH NEUROLEPTIC MALIGNANT SYNDROME [J].

RAM, A ;

CAO, QH ;

KECK, PE ;

POPE, HG ;

OTANI, K ;

ADDONIZIO, G ;

MCELROY, SL ;

KANEKO, S ;

REDLICHOVA, M ;

GERSHON, ES ;

GEJMAN, PV .

AMERICAN JOURNAL OF MEDICAL GENETICS, 1995, 60 (03) :228-230